Trial Profile

A 2-Year Prospective Study to Assess Health-related Quality of Life In Subjects With Highly-Active Relapsing Multiple Sclerosis Treated With Mavenclad (CLARIFY MS)

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 11 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

27 Jan 2024 This trial has been completed in Portugal, according to European Clinical Trials Database record.
13 Oct 2023 Results (n=482) of a post-hoc analysis assessing improvements in their overall health-related quality of life over two year of period presented at the 9th Triennial joint meeting of Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis
25 Feb 2023 Results of the effect of CladT on cognitive function , presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Forum 2023

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com